Smith & Nephew (LON:SN) Hits New 52-Week High – Here’s What Happened

Smith & Nephew plc (LON:SN)’s stock price hit a new 52-week high during trading on Wednesday . The stock traded as high as GBX 1,258.50 and last traded at GBX 1,255, with a volume of 2359560 shares changing hands. The stock had previously closed at GBX 1,256.

Analyst Ratings Changes

A number of brokerages recently issued reports on SN. Royal Bank Of Canada cut shares of Smith & Nephew to a “sector perform” rating and dropped their target price for the stock from GBX 1,700 to GBX 1,350 in a research report on Wednesday, December 17th. Panmure Gordon reaffirmed a “hold” rating and set a GBX 1,200 price objective on shares of Smith & Nephew in a report on Tuesday, December 9th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Smith & Nephew in a research note on Friday, November 7th. Finally, Citigroup increased their price target on Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a research report on Friday, October 31st. Two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Smith & Nephew presently has a consensus rating of “Hold” and a consensus price target of GBX 1,381.33.

Smith & Nephew Stock Performance

The stock’s 50 day simple moving average is GBX 1,258.26 and its two-hundred day simple moving average is GBX 1,273.49. The company has a market capitalization of £13.76 billion, a P/E ratio of 45.18, a P/E/G ratio of 0.46 and a beta of 0.62. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84.

Insider Transactions at Smith & Nephew

In other Smith & Nephew news, insider Deepak Nath sold 1,240 shares of the stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total value of £15,586.80. Corporate insiders own 0.19% of the company’s stock.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.